Sumitomo Pharma Co., Ltd. (4506.T)
JPY 575.0
(-0.69%)
JPY 575.0
(-0.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -354.19 Billion JPY | -360.12% |
| 2022 | -76.97 Billion JPY | -227.8% |
| 2021 | 60.23 Billion JPY | -15.43% |
| 2020 | 71.22 Billion JPY | -14.43% |
| 2019 | 83.23 Billion JPY | 43.8% |
| 2018 | 57.88 Billion JPY | -34.35% |
| 2017 | 88.17 Billion JPY | 67.12% |
| 2016 | 52.75 Billion JPY | 42.87% |
| 2015 | 36.92 Billion JPY | 58.66% |
| 2014 | 23.27 Billion JPY | -44.77% |
| 2013 | 42.14 Billion JPY | 68.28% |
| 2012 | 25.04 Billion JPY | 22.75% |
| 2011 | 20.4 Billion JPY | -34.08% |
| 2010 | 30.95 Billion JPY | -13.12% |
| 2009 | 35.62 Billion JPY | 14.3% |
| 2008 | 31.16 Billion JPY | -21.72% |
| 2007 | 39.81 Billion JPY | -12.6% |
| 2006 | 45.55 Billion JPY | 57.71% |
| 2005 | 28.88 Billion JPY | 149.34% |
| 2004 | 11.58 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.09 Billion JPY | -63.93% |
| 2024 Q1 | -3.1 Billion JPY | 98.65% |
| 2023 Q3 | -31.24 Billion JPY | 10.55% |
| 2023 Q2 | -34.93 Billion JPY | 32.26% |
| 2023 Q1 | -51.56 Billion JPY | 12.9% |
| 2023 Q4 | -230.82 Billion JPY | -638.72% |
| 2023 FY | -354.19 Billion JPY | -360.12% |
| 2022 Q2 | -43.52 Billion JPY | -397.86% |
| 2022 Q1 | 14.61 Billion JPY | 628.51% |
| 2022 Q4 | -59.2 Billion JPY | -631.53% |
| 2022 FY | -76.97 Billion JPY | -227.8% |
| 2022 Q3 | 11.13 Billion JPY | 125.59% |
| 2021 Q4 | 2 Billion JPY | -81.17% |
| 2021 FY | 60.23 Billion JPY | -15.43% |
| 2021 Q1 | 8.3 Billion JPY | 150.92% |
| 2021 Q2 | 39.26 Billion JPY | 372.74% |
| 2021 Q3 | 10.65 Billion JPY | -72.86% |
| 2020 FY | 71.22 Billion JPY | -14.43% |
| 2020 Q1 | 23.27 Billion JPY | 1208.83% |
| 2020 Q2 | 24.26 Billion JPY | 4.28% |
| 2020 Q3 | 39.99 Billion JPY | 64.81% |
| 2020 Q4 | -16.31 Billion JPY | -140.78% |
| 2019 FY | 83.23 Billion JPY | 43.8% |
| 2019 Q1 | 40.42 Billion JPY | 265.72% |
| 2019 Q2 | 26.41 Billion JPY | -34.66% |
| 2019 Q3 | 14.62 Billion JPY | -44.62% |
| 2019 Q4 | 1.77 Billion JPY | -87.84% |
| 2018 Q1 | 15.81 Billion JPY | -50.93% |
| 2018 FY | 57.88 Billion JPY | -34.35% |
| 2018 Q2 | 13.79 Billion JPY | -12.78% |
| 2018 Q3 | 17.22 Billion JPY | 24.87% |
| 2018 Q4 | 11.05 Billion JPY | -35.83% |
| 2017 FY | 88.17 Billion JPY | 67.12% |
| 2017 Q4 | 32.23 Billion JPY | 182.08% |
| 2017 Q3 | 11.42 Billion JPY | -58.97% |
| 2017 Q2 | 27.84 Billion JPY | 41.12% |
| 2017 Q1 | 19.73 Billion JPY | 131.64% |
| 2016 Q3 | 17.51 Billion JPY | 43.81% |
| 2016 Q1 | 14.55 Billion JPY | 149.1% |
| 2016 Q4 | 8.51 Billion JPY | -51.35% |
| 2016 FY | 52.75 Billion JPY | 42.87% |
| 2016 Q2 | 12.17 Billion JPY | -16.34% |
| 2015 FY | 36.92 Billion JPY | 58.66% |
| 2015 Q4 | 5.84 Billion JPY | -58.96% |
| 2015 Q3 | 14.23 Billion JPY | 14.78% |
| 2015 Q2 | 12.4 Billion JPY | 179.27% |
| 2015 Q1 | 4.44 Billion JPY | 871.99% |
| 2014 Q2 | 3.25 Billion JPY | -62.61% |
| 2014 Q3 | 10.87 Billion JPY | 234.45% |
| 2014 Q4 | 457 Million JPY | -95.8% |
| 2014 FY | 23.27 Billion JPY | -44.77% |
| 2014 Q1 | 8.69 Billion JPY | 16.07% |
| 2013 Q3 | 17.21 Billion JPY | 104.79% |
| 2013 FY | 42.14 Billion JPY | 68.28% |
| 2013 Q2 | 8.4 Billion JPY | -6.88% |
| 2013 Q1 | 9.02 Billion JPY | 217.86% |
| 2013 Q4 | 7.49 Billion JPY | -56.5% |
| 2012 Q1 | 10.88 Billion JPY | 666.09% |
| 2012 Q2 | 9.09 Billion JPY | -16.48% |
| 2012 Q3 | 12.72 Billion JPY | 39.96% |
| 2012 Q4 | -7.66 Billion JPY | -160.2% |
| 2012 FY | 25.04 Billion JPY | 22.75% |
| 2011 Q1 | 12.78 Billion JPY | 228.97% |
| 2011 Q3 | 7.59 Billion JPY | 291.9% |
| 2011 Q4 | -1.92 Billion JPY | -125.31% |
| 2011 FY | 20.4 Billion JPY | -34.08% |
| 2011 Q2 | 1.93 Billion JPY | -84.84% |
| 2010 Q4 | 3.88 Billion JPY | -67.92% |
| 2010 FY | 30.95 Billion JPY | -13.12% |
| 2010 Q2 | 147 Million JPY | -99.01% |
| 2010 Q1 | 14.79 Billion JPY | 306.32% |
| 2010 Q3 | 12.11 Billion JPY | 8141.5% |
| 2009 FY | 35.62 Billion JPY | 14.3% |
| 2009 Q4 | 3.64 Billion JPY | -72.14% |
| 2009 Q3 | 13.06 Billion JPY | 70.1% |
| 2009 Q2 | 7.68 Billion JPY | -31.65% |
| 2009 Q1 | 11.23 Billion JPY | 210.33% |
| 2008 Q2 | 7.96 Billion JPY | 0.0% |
| 2008 Q4 | 3.62 Billion JPY | -61.34% |
| 2008 Q3 | 9.36 Billion JPY | 17.65% |
| 2008 FY | 31.16 Billion JPY | -21.72% |
| 2007 FY | 39.81 Billion JPY | -12.6% |
| 2006 FY | 45.55 Billion JPY | 57.71% |
| 2005 FY | 28.88 Billion JPY | 149.34% |
| 2004 FY | 11.58 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 7027.323% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 265.453% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 306.575% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -181063.208% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 1228.51% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 3823.263% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 763.185% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 49568.436% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 2790.013% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 6203.636% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 18134.318% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -71599.19% |
| Tsumura & Co. | 20.01 Billion JPY | 1869.378% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 8917.376% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 7133.241% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 2106.992% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 9280.767% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 3745.229% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 5990.471% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | -11403.54% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 9195.891% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | -43537.793% |
| MedRx Co., Ltd | -933 Million JPY | -37862.915% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 6974.9% |
| Solasia Pharma K.K. | -1.13 Billion JPY | -30996.927% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | -14844.895% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 5549.138% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 1975.432% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -50685.089% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 1932.259% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 8182.349% |